Based in Finland, Aprovix is a startup.
Aprovix develops Qvintip®, a clinically validated, single-use self-sampling device for HPV detection designed to increase access to cervical cancer screening by enabling at-home HPV testing with clinical accuracy comparable to clinician-collected samples.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.